Wegovy mg strengths: what each dose is for and how the schedule works

The biggest myth about Wegovy doses: higher mg does not simply mean faster results

The most common misunderstanding is that patients should push for the highest dose as quickly as possible. The titration schedule exists precisely because semaglutide's most common side effects (nausea, loose stools, stomach discomfort) are strongly linked to how fast the dose rises, not to the dose itself once you have adapted to it. Rushing from 0.25mg to 2.4mg in a few weeks would almost certainly produce more GI upset, and in practice tends to cause people to stop treatment earlier than they otherwise would.

The licensed schedule, as described on the NHS semaglutide medicines page, moves through each strength at roughly four-week intervals: 0.25mg to 0.5mg, then 1mg, 1.7mg, and finally 2.4mg as the standard maintenance dose. Most of the therapeutic weight-loss effect builds during the maintenance phase, not the early weeks. The 0.25mg starting pen is designed for adjustment rather than treatment in the headline sense, and understanding what that first dose is actually doing helps set realistic expectations from the outset.

It is also worth knowing that not everyone reaches 2.4mg. If a lower strength is well tolerated and producing a clinical response, your prescriber may hold you there. Conversely, if side effects at a given dose are difficult, staying at the previous strength a little longer is a recognised clinical option. The mg figure on the box is a waypoint, not a finish line.

What the 7.2mg approval adds, and who it is actually for

The MHRA approved a single-dose 7.2mg Wegovy pen on 14 April 2026, making the UK the first country in Europe to licence it. The pen uses an auto-dosing mechanism with a built-in covered needle that locks after use, so the full 7.2mg is delivered in one weekly injection. It is licensed specifically for adults with a BMI of 30 or above; it is not available for the cardiovascular indication or for lower BMI thresholds.

The clinical trial data behind this approval, as reported in the gov.uk announcement of the 7.2mg pen's approval, showed around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide's results in comparable trials. That figure comes from participants who followed the full protocol; individual outcomes vary, and no treatment guarantees a specific result.

Starting dose remains 0.25mg even for patients who will eventually reach 7.2mg. The titration steps up through the same schedule before 7.2mg becomes an option. If you are currently on treatment elsewhere and considering a transfer to Wegovy through a UK-registered provider, the dose you have reached is part of the clinical picture any new prescriber will need to assess. Specific dose and pen format availability is always confirmed at consultation rather than assumed in advance.

Semaglutide dose confusion: Wegovy mg versus Ozempic and Rybelsus strengths

Semaglutide comes in more than one branded product, and the mg numbers overlap in ways that cause genuine confusion. Ozempic (0.25mg, 0.5mg, 1mg, 2mg) is licensed for type 2 diabetes in the UK, not for weight management. Rybelsus (3mg, 7mg, 14mg) is an oral tablet also licensed for diabetes only. Neither is a route to a weight-loss prescription through a UK pharmacy.

Wegovy's injectable strengths and the newer oral Wegovy tablet (1.5mg, 4mg, 9mg and 25mg, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK) are the semaglutide products licensed for weight loss. If you read about semaglutide dose ranges online and the numbers don't match what your provider has given you, it is likely because the source was describing a different product or a different indication altogether.

Understanding the full picture of semaglutide as a medicine helps here, the mechanism is the same across products, but the licensed use, the dose range, and what a prescriber can legally offer you are not. A question our prescribers hear regularly is whether a patient can switch between these products; the answer depends on clinical assessment, not simply which mg figure is closest.

What the dose schedule means in practice if you are considering Wegovy privately

Private Wegovy prescriptions follow the same licensed titration as NHS prescriptions; the schedule is not shortened because you are paying. What differs is the absence of a waiting list and the lack of a specialist-referral requirement. The eligibility criteria for Wegovy in a private setting are set by the medicine's licence: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, high cholesterol or obstructive sleep apnoea.

If you want to understand what private treatment typically costs before committing to a consultation, the cost context page explains how private Wegovy pricing works and what a legitimate price should include. On the clinical side, every repeat prescription at nume is reviewed by a named GPhC-registered Independent Prescriber before it is issued, which means dose changes are assessed on clinical grounds each time, not automatically processed. That review is what the titration schedule is designed to support.

The 2.4mg maintenance dose is where most patients settle for the longer term, though with 7.2mg now licensed, some may progress further under clinical guidance. If you are ready to understand whether Wegovy is right for you, speaking to a prescriber is the only way to get an answer specific to your health picture.